Neurological disorders, ranging from acute forms such as stroke and traumatic brain injury to neurodegenerative diseases like dementia, are the leading cause of disability-adjusted life years (DALYs) worldwide. A promising approach to address these conditions and promote nervous system regeneration is the use of the neuropeptide preparation Cerebrolysin, which has been shown to be effective in both clinical and preclinical studies. Despite claims of similar clinical efficacy and safety by several peptide preparations, concerns regarding their generic composition and efficacy have been previously raised. Based on these reports, we analyzed the peptide composition and neurotrophic activity of several peptide preparations allegedly similar to Cerebrolysin and approved in some countries for treating neurological diseases. Our results demonstrate that these preparations lack relevant biological activity and that the peptide composition is significantly different from Cerebrolysin. peptide.
Keywords: Cerebrolysin; DALYs; Disability-Adjusted Life Years; EGFP; Enhanced Green Fluorescent Protein; HPLC; High Performance Liquid Chromatography; NF-L; Neurofilament-L; PC12; Rat Pheochromocytoma Cell Line; bioassay; cerebroprotein hydrolysate; neuronal differentiation; porcine brain.
© 2024 by the authors.